1. United States of America Stocks

  2. •

    Technology

  3. •

    Hardware, Equipment & Parts
Microart Inc.

Microart Inc.

MCRT
Microart Inc.US flagOther OTC
0.00
USD
- -
- -
26,149.00Market Cap
Microart Inc.
MCRT
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Similar Companies
Kaimei Electronic Corp. (2375.TW)
Yimikang Tech.Group Co., Ltd. (300249.SZ)
Hosiden Corporation (6804.T)
Ji-Haw Industrial Co.,Ltd. (3011.TW)
Syntec Optics Holdings, Inc. (OPTXW)
Quanergy Systems, Inc. (QNGY-WT)
Business
Microart Inc. (MCRT) researches and develops innovative stem cell solutions and therapeutic applications of adult stem cells; the company develops and commercializes cell-based anti-aging research and cosmetic products; it also advances proprietary technology for diabetes treatment. Founded in 1980 and headquartered at 2611 Office Tower, Langham Place, Kowloon City, Kowloon, Hong Kong, Microart operates in the biotechnology and healthcare sectors, targeting anti-aging, cosmetics, and therapeutic markets with a focus on adult stem cell innovations. The company maintains a minimal market capitalization of approximately US$130 with no reported revenue or earnings in recent trailing twelve-month periods, reflecting its early-stage research emphasis. No major recent partnerships, acquisitions, funding rounds, product launches, or strategic shifts have been publicly disclosed within the last 1-2 years, underscoring a period of operational stability amid limited financial activity.